NASDAQ:ARAV Aravive (ARAV) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free ARAV Stock Alerts $0.04 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage VolumeN/AMarket Capitalization$2.95 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Aravive alerts: Email Address Aravive MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside33,565.8% Upside$13.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.29 out of 5 stars 3.0 Analyst's Opinion Consensus RatingAravive has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAravive has received no research coverage in the past 90 days.Read more about Aravive's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ARAV. Previous Next 0.0 Dividend Strength Dividend YieldAravive does not currently pay a dividend.Dividend GrowthAravive does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAravive has received a 71.21% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aravive is -0.77. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 4 people have added Aravive to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aravive insiders have not sold or bought any company stock.Percentage Held by Insiders60.40% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.80% of the stock of Aravive is held by institutions.Read more about Aravive's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aravive is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAravive has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aravive's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before… Click here now to download the free Precious Metals Buying Guide. About Aravive Stock (NASDAQ:ARAV)Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Read More ARAV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARAV Stock News HeadlinesApril 23, 2024 | finance.yahoo.comPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 2, 2024 | finance.yahoo.comDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightJanuary 30, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 18, 2024 | msn.comCrude Oil Rises Over 1%; Processa Pharmaceuticals Shares SlideJanuary 18, 2024 | msn.comWhy Is Nuvve (NVVE) Stock Down 31% Today?January 18, 2024 | markets.businessinsider.comWhy Is Aravive (ARAV) Stock Down 52% Today?January 17, 2024 | marketwatch.comAravive Shares Drop 53%, Company to Delist and Deregister StockJanuary 17, 2024 | finance.yahoo.comAravive, Inc. to Delist from The Nasdaq Stock MarketDecember 27, 2023 | benzinga.comAravive Stock (NASDAQ:ARAV), Short Interest ReportDecember 27, 2023 | benzinga.comAravive Stock (NASDAQ:ARAV) Dividends: History, Yield and DatesDecember 8, 2023 | bizjournals.comHouston is building it. Why won't they come?November 20, 2023 | bizjournals.comHouston companies, universities win nearly $50.7 million in latest CPRIT awardsNovember 12, 2023 | morningstar.comAravive Inc ARAVOctober 13, 2023 | finance.yahoo.comAravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?September 24, 2023 | finance.yahoo.comAravive, Inc. (ARAV) Stock Historical Prices & Data - Yahoo FinanceAugust 29, 2023 | benzinga.comThinking about buying stock in Limbach Holdings, Aravive, Up Fintech Holding, YS Biopharma, or Big Lots?August 23, 2023 | 247wallst.comCantor Fitzgerald Downgrades AraviveAugust 22, 2023 | msn.comCantor Fitzgerald Downgrades Aravive (ARAV)August 22, 2023 | msn.comCantor cuts Aravive to neutral as biotech struggles to stay in businessAugust 22, 2023 | markets.businessinsider.comAnalyst Downgrades Aravive: Grapples With Trial Setback, Strategic AlternativesAugust 4, 2023 | msn.comWilliam Blair Downgrades Aravive (ARAV)August 3, 2023 | msn.comAravive (ARAV) Price Target Decreased by 5.77% to 12.50August 3, 2023 | seekingalpha.comAravive sinks as Phase 3 ovarian cancer trial for lead asset failsAugust 3, 2023 | msn.comAravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian CancerAugust 3, 2023 | marketwatch.comAravive Shares Hit 52-Week Low After Trial Misses Primary EndpointSee More Headlines Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today6/15/2024Next Earnings (Estimated)6/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARAV CUSIPN/A CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$18.00 Low Stock Price Target$9.00 Potential Upside/Downside+33,565.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,320,000.00 Net Margins-569.65% Pretax Margin-569.65% Return on EquityN/A Return on Assets-99.65% Debt Debt-to-Equity RatioN/A Current Ratio0.98 Quick Ratio0.98 Sales & Book Value Annual Sales$9.14 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book0.22Miscellaneous Outstanding Shares73,560,000Free Float29,131,000Market Cap$2.95 million OptionableOptionable Beta2.10 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Fredric N. Eshelman Pharm.D. (Age 75)Executive Chairman Comp: $95kDr. Jeffrey L. Cleland Ph.D. (Age 59)Co-Founder Comp: $669.98kDr. Joshua Aaron Silverman Ph.D.Co-FounderMr. Marek Ciszewski J.D.Vice President of Investor RelationsKey CompetitorsElevai LabsNASDAQ:ELABVaccinexNASDAQ:VCNXAvalo TherapeuticsNASDAQ:AVTXMIRA PharmaceuticalsNASDAQ:MIRAChemomab TherapeuticsNASDAQ:CMMBView All Competitors ARAV Stock Analysis - Frequently Asked Questions Should I buy or sell Aravive stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ARAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARAV, but not buy additional shares or sell existing shares. View ARAV analyst ratings or view top-rated stocks. What is Aravive's stock price target for 2024? 4 Wall Street research analysts have issued 12-month target prices for Aravive's stock. Their ARAV share price targets range from $9.00 to $18.00. On average, they expect the company's share price to reach $13.50 in the next year. This suggests a possible upside of 33,565.8% from the stock's current price. View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts. How have ARAV shares performed in 2024? Aravive's stock was trading at $0.1237 at the beginning of the year. Since then, ARAV shares have decreased by 67.6% and is now trading at $0.0401. View the best growth stocks for 2024 here. When is Aravive's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 19th 2024. View our ARAV earnings forecast. How were Aravive's earnings last quarter? Aravive, Inc. (NASDAQ:ARAV) issued its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The firm had revenue of $2.41 million for the quarter, compared to analyst estimates of $2.36 million. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX). How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARAV) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.